NOVARTIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 93.37 CHF | +0.81% |
|
+1.14% | +10.02% |
| 16/05 | Dpa-AFX Overview: COMPANIES from 16.05.2024 - 15:15 | DP |
| 16/05 | Novartis: presents results of tender offer for MorphoSysy | CF |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 48.92B 44.48B 4,075B | Sales 2025 * | 50.86B 46.23B 4,236B | Capitalization | 210B 191B 17,482B |
|---|---|---|---|---|---|
| Net income 2024 * | 10.42B 9.48B 868B | Net income 2025 * | 11.92B 10.84B 993B | EV / Sales 2024 * | 4.54 x |
| Net Debt 2024 * | 12.44B 11.31B 1,036B | Net Debt 2025 * | 11.34B 10.31B 945B | EV / Sales 2025 * | 4.35 x |
| P/E ratio 2024 * |
20.1
x | P/E ratio 2025 * |
17.2
x | Employees | 76,057 |
| Yield 2024 * |
3.51% | Yield 2025 * |
3.64% | Free-Float | 85.22% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novartis AG
More recommendations
More press releases
More news
| 1 day | +0.81% | ||
| 1 week | +1.14% | ||
| Current month | +4.85% | ||
| 1 month | +9.17% | ||
| 3 months | +4.25% | ||
| 6 months | +11.02% | ||
| Current year | +10.02% |
1 week
92.44
93.85
1 month
85.4493.85
Current year
83.6394.52
1 year
83.0094.77
3 years
72.8494.77
5 years
65.0996.38
10 years
65.09103.20
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 01/05/01 | |
| Director of Finance/CFO | 59 | 01/03/01 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 16/22/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 01/13/01 |
Simon Moroney
BRD | Director/Board Member | 65 | 28/20/28 |
| Chairman | 68 | 01/13/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 10.40% | 121 M€ | -.--% | - | |
| 5.57% | 17 M€ | +7.69% | - | |
| 4.12% | 88 M€ | +10.37% | - | |
| 3.79% | 2 M€ | -25.75% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/24/17 | 93.37 | +0.81% | 3,439,522 |
| 16/24/16 | 92.62 | -0.73% | 2,832,960 |
| 15/24/15 | 93.3 | -0.20% | 2,511,921 |
| 14/24/14 | 93.49 | +0.45% | 2,742,580 |
| 13/24/13 | 93.07 | +0.81% | 3,892,615 |
Delayed Quote Swiss Exchange, May 17, 2024 at 09:00 pm IST
More quotes
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows:
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
102.9
USD
Average target price
107.9
USD
Spread / Average Target
+4.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.02% | 210B | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +8.49% | 168B | |
| -0.52% | 162B |
- Stock Market
- Equities
- NOVN Stock
